HROW חוב כולל להון Harrow Corp

Harrow, Inc. relies on stable demand from ophthalmology clinics, which ensures a predictable cash flow. High scientific and technical potential is supported by investments in automation and advanced formulations. The creation of combination products simplifies postoperative eye care. The total debt-to-equity ratio clearly demonstrates the credit load, where the 18.88 metric determines this level.

An investment audit of the issuer requires a deep analysis of its liability structure prior to asset acquisition. This metric is calculated as the ratio of total borrowed funds to equity, determining the business's degree of financial autonomy. For Harrow, Inc. (HROW), this balance is critical when financing R&D and the commercialization of ophthalmological drugs. Rising leverage could restrict the budget for launching new eye drops. The historical debt-to-equity ratio clearly demonstrates the resilience of the company's development model.